1-2 of 2
Brian Keogh
Close
Sort by
Journal Articles

A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy

Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Marina Y. Konopleva, MD PhD, Naval G. Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MDMSc, Prithviraj Bose, MD, Parita Patel, Rami S. Komrokji, MD, Aditi Shastri, MD, Gail J. Roboz, MD, Robert Matthew Miller, MD, Sarah Arbe-Barnes, PhD, Mary Reilly, MSc, Peter McGuirk, PhD, Tara Kearney, Brian Keogh, PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 798.
https://doi.org/10.1182/blood-2018-99-119805
Published: 2018
Journal Articles

A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy

Guillermo Garcia-Manero, MD, Guillermo Montalban-Bravo, MD, Hui Yang, MD PhD, Yue Wei, PhD, Yesid Alvarado, MD, Courtney D. DiNardo, MD MSCE, Naval G. Daver, MD, Marina Konopleva, MD PhD, Katherine P. Hearn, BSN, RN, Robert Miller, Sarah Arbe-Barnes, Peter Mc Guirk, Tara Kearney, Brian Keogh, Hagop M. Kantarjian, MD, Mary Reilly
Journal: Blood
Blood (2016) 128 (22): 227.
https://doi.org/10.1182/blood.V128.22.227.227
Published: 2016